Results 51 to 60 of about 31,390 (228)

CD39 in the development and progression of pulmonary arterial hypertension

Purinergic Signalling, 2022
AbstractPulmonary arterial hypertension (PAH) is a devastating progressive disease characterised by pulmonary arterial vasoconstriction and vascular remodelling. Endothelial dysfunction has emerged as a contributing factor in the development of PAH. However, despite progress in the understanding of the pathophysiology of this disease, current therapies
Willcox, Abbey, Lee, Natasha Ting, Nandurkar, Harshal H., Sashindranath, Maithili   +3 more
openaire   +2 more sources

On the mechanism of anti-CD39 immune checkpoint therapy [PDF]

Journal for ImmunoTherapy of Cancer, 2020
With the coming of age of cancer immunotherapy, the search for new therapeutic targets has led to the identification of immunosuppressive adenosine as an important regulator of antitumor immunity. This resulted in the development of selective inhibitors targeting various components of the adenosinergic pathway, including small molecules antagonists ...
John Stagg, Bertrand Allard, David Allard   +2 more
openaire   +3 more sources

Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis [PDF]

, 2008
Concanavalin A (Con A)-induced injury is an established natural killer T (NKT) cell-mediated model of inflammation that has been used in studies of immune liver disease.
Robson, Simon C., Beldi, Guido, Enjyoji, Keiichi, Yegutkin, Gennady G, Simon C. Robson, Michael Nowak, Banz, Yara, Candinas, Daniel, Yan Wu, Lindsay Miller, Miller, Lindsay, Guido Beldi, Keiichi Enjyoji, Arvand Haschemi, Yegutkin, Gennady G., Wu, Yan, Robson, Simon C, Nowak, Michael, Exley, Mark, Haschemi, Arvand, Daniel Candinas, Yara Banz, Gennady G. Yegutkin, Mark Exley   +23 more
core   +1 more source

Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity

Journal for ImmunoTherapy of Cancer, 2019
Background Cancer cells are known to develop mechanisms to circumvent effective anti-tumor immunity. The two ectonucleotidases CD39 and CD73 are promising drug targets, as they act in concert to convert extracellular immune-stimulating ATP to adenosine ...
Abhishek S. Kashyap, Tamara Thelemann, Richard Klar, Sandra M. Kallert, Julia Festag, Melanie Buchi, Lisa Hinterwimmer, Monika Schell, Sven Michel, Frank Jaschinski, Alfred Zippelius   +10 more
doaj   +1 more source

A Novel Prognostic Biomarker of Luminal Breast Cancer: High CD39 Expression Is Related to Poor Survival

Frontiers in Genetics, 2021
BackgroundCD39 is one of the functional surface markers for T regulatory cells, the prognostic role and immune-related effects of CD39 in luminal breast cancer (BC) patients has not been evaluated yet.
Xiaojian Ni, Xiaojian Ni, Wenze Wan, Wenze Wan, Jingjing Ma, Xinyou Liu, Bohao Zheng, Bohao Zheng, Zhixian He, Weige Yang, Weige Yang, Weige Yang, Lihong Huang, Lihong Huang   +13 more
doaj   +1 more source

Tumor‐Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development

Advanced Science, EarlyView.
A single‐cell atlas of pancreatic ductal adenocarcinoma development reveals progressive ductal‐fibroblast‐immune crosstalk. Tumor‐derived LAMB3 drives the formation of immunosuppressive LRRC15+ fibroblasts through the ITGB1/FAK/MAPK/FOSL2 signaling. Glycolytic reprogramming upregulates LAMB3 and correlates with LRRC15+ fibroblast enrichment.
Xuqing Shi, Hangqi Liu, Jianru Sun, Xiaoding Liu, Xinping Jv, Longyun Chen, Yuhan Zhang, Hui Zhang, Xudong Xing, Ruiyu Li, Xinyi Ke, Jun Wang, Xianglin Yin, Bohan Liu, Qixian Liu, Yuan Wang, Junliang Lu, Shiyi Liu, Junyi Pang, Yumeng Cai, Menghua Dai, Fan Bai, Huanwen Wu, Zhiyong Liang   +23 more
wiley   +1 more source

CD25+CD134+ CD39+FoxP3+ cells have bona fide Tregs phenotype. [PDF]

, 2018
(A) Gating strategy used for detecting CMV-specific CD4+CD25+CD134+ CD39+FoxP3+ Tregs, and IFN-γ producing CD25+CD134+CD39-FoxP3- and CD25+CD134+ CD39-FoxP3+. PBMCs from CMV+ individuals were stimulated with CMV lysate for 44hrs.
Yves Levy (119516), Jean-Daniel Lelièvre (3173220), Vedran Brezar (337452), Nabila Seddiki (214661), Christine Lacabaratz (567696), Lylia Hani (4249249), Mathieu Surenaud (78141), Audrey Hubert (4249252)   +7 more
core   +1 more source

Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma

Cell Reports Medicine
Summary: CD39+CD8+ T cells are known as tumor-antigen-specific cells among CD8+ tumor-infiltrating lymphocytes (TILs). However, CD39+CD8+ T cells also reportedly exhibit immunosuppressive activity in hypoxic tumor models.
Yong Joon Lee, Seung Hyuck Jeon, Jin Hee Yeo, Sun-ju Byeon, Jae Hyung Jung, Heejin Nam, Minwoo Jeon, Eui-Soon Kim, Jeon Yeob Jang, Chul-Ho Kim, Kee Yang Chung, Jung Yun Lee, Shin Hwang, Jee Ye Kim, Seung-Il Kim, Jae-Ho Cheong, Chang Gon Kim, Sang Joon Shin, Su-Hyung Park, Minsun Jung, Minyong Kang, Seong Il Seo, Eui-Cheol Shin   +22 more
doaj   +1 more source

Purinergic Signaling as a Regulator of Th17 Cell Plasticity. [PDF]

PLoS ONE, 2016
T helper type 17 (Th17) lymphocytes, characterized by the production of interleukin-17 and other pro-inflammatory cytokines, are present in intestinal lamina propria and have been described as important players driving intestinal inflammation.
Dominique Fernández, Felipe Flores-Santibáñez, Jocelyn Neira, Francisco Osorio-Barrios, Gabriela Tejón, Sarah Nuñez, Yessia Hidalgo, Maria Jose Fuenzalida, Daniel Meza, Gonzalo Ureta, Alvaro Lladser, Rodrigo Pacheco, Claudio Acuña-Castillo, Victoria Guixé, Francisco J Quintana, Maria Rosa Bono, Mario Rosemblatt, Daniela Sauma   +17 more
doaj   +1 more source

Material‐Encoded Synchronization of Immunogenic Cell Death With Adenosine A2A Receptor Blockade Reprograms the Tumor Microenvironment

Advanced Science, EarlyView.
A bismuth–copper diselenide–based nanoplatform (BSCS@PHY) coordinates immunogenic cell death with local A2A receptor blockade in 4T1 tumors. Thermally triggered shell melting exposes catalytic surfaces for glutathione depletion and chemodynamic ROS generation, while co‐delivering an A2AR antagonist and yeast‐wall adjuvant to enhance dendritic‐cell ...
Xiangting Yi, Hanlou Yang, Junting Huang, Pengfei Wu, Shiying Zhou, Zunde Liao, Min Han, Zishan Chen, Xiaoyu Huang, Nan Ma, Jie Zhou, Mingqiang Li, Yiling Zhong   +12 more
wiley   +1 more source